First Subject Dosed in Lipigon's Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical's LNAplus(TM) Technology Platform

First Subject Dosed in Lipigon's Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical's LNAplus(TM) Technology Platform
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.